GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Receivables

HURA (TuHURA Biosciences) Total Receivables : $0.44 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Total Receivables?

TuHURA Biosciences's Total Receivables for the quarter that ended in Dec. 2024 was $0.44 Mil.


TuHURA Biosciences Total Receivables Historical Data

The historical data trend for TuHURA Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Total Receivables Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Receivables
- - 0.33 0.44

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only 0.33 0.33 0.22 0.26 0.44

TuHURA Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


TuHURA Biosciences Total Receivables Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.